Clinical Impact of Thoracic Scanographic Characteristics of Hematologic Malignancy Patients

Recruiting Observational Study
Mediastinal Diseases
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
16 and older
Sex
Any
Study type
Observational
Participants needed
125 (estimated)
Sponsor
University Hospital, Toulouse · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The mediastinum can be the site of benign or malignant tumors, including 10 to 20% of hematological malignancies. Mediastinal mass syndrome (MMS) includes symptoms due to irritation, invasion or compression of the organs of the mediastinum. This syndrome includes respiratory manifestations that may be secondary to compression of the tracheobronchial tree, venous vascular manifestations with the s…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Hematologic malignancy at diagnosis or relapse * Symptomatic mediastinal mass syndrome * Admission to the ICU, Continuous Medical Surveillance (CMS) or Intensive Care (IC) for symptomatology related to MMS * Chest CT (after maximum 48 hours of corticosteroid therapy (1mg/kg/ P…
Contacts

Muriel Picard, MD

0561756105

picard.m@chu-toulouse.fr

CONTACT